


Results



Predicting liver-mediated drug-drug interactions with NRI: A first-in-human study Results

by

miblab.org

Report compiled by: Steven Sourbron

Institute: University of Sheffield

Department: Section of Medical Imaging and Technologies

Email: s.sourbron@sheffield.ac.uk
Date: Monday 26th May, 2025



Contents

1	l Figures	1
2	2 Tables	6
3	3 Supplements	11

Tigures




Figure 1.1: Visualisation of the primary endpoints khe and kbh across the population, showing a significant response to drug: (a) the relative and absolute effect size across the population as box plots; and (b) the individual values at control (left of plots) and after single dose of drug (right of plot). Colored lines in (b) represent individual volunteers. Note: absolute effect sizes for kbh have been scaled with a factor 10 to improve visualisation.




Figure 1.2: drug effect for all parameters that show a significant reduction in the mean value (p<0.01). The top row shows the difference relative to the standard error of the difference, and the bottom row shows the individual effects for the corresponding biomarkers.




Figure 1.3: Correlations between parameters at control.




Figure 1.4: Correlations between parameter changes.

Tables

parameter	count	mean	std	min	25%	50%	75%	max
Age (yr)	10.0	32.5	8.3	21.0	27.0	32.0	35.5	51.0
ALP(U/L)	10.0	67.8	26.5	39.5	53.4	60.0	67.5	118.0
ALT (U/L)	10.0	20.8	8.2	14.0	16.5	17.8	23.4	41.5
Albumin (g/L)	10.0	42.3	2.8	37.0	41.8	42.8	43.4	46.0
Bilirubin (umol/L)	10.0	13.0	4.2	6.5	10.8	12.8	14.0	23.0
Conjugated Bilirubin (umol/L)	10.0	4.7	2.1	3.0	3.5	4.2	5.0	10.0
Conjugated/total bilirubin (%)	10.0	36.2	6.4	25.0	33.4	36.2	39.0	46.5
BMI (kg/m2)	10.0	24.4	3.5	18.7	22.6	24.0	26.8	30.0
Creatinine (umol/L)	10.0	77.1	13.3	58.0	67.2	79.5	86.8	98.0
Height (cm)	10.0	174.3	8.1	163.1	167.6	175.7	179.9	187.8
Urea nitrogen (mmol/L)	10.0	5.8	1.5	3.4	5.0	5.8	7.0	7.8
Body weight (kg)	10.0	73.2	7.6	57.0	72.8	74.6	75.9	82.8

 Table 2.1: Demographics of the study population.

parameter	V1	V2	Diff	р
ALP	67.6 (40.1)	69.4 (54.1)	1.8 (23.1)	0.687
ALT	21.8 (18.7)	25.4 (18.9)	3.6 (9.4)	0.069
Alb	44.5 (4.1)	43.9 (5.9)	-0.6 (6.3)	0.598
Bili	12.1 (8.5)	11.4 (9.3)	-0.8 (11.6)	0.731
ConBili	4.8 (3.7)	4.6 (4.2)	-0.1 (5.1)	0.89
ConTotBili	39.4 (11.3)	37.3 (9.1)	-3.0 (15.6)	0.358

 Table 2.2: LFT changes between both visits.

Name	Group	control	drug	Effect size (%)	Т	p-value
Bilirubin	Blood	13.0 (2.6)	22.0 (2.8)	81.9 (52.0)	-5.4	0.001
(umol/L)	- liver	, ,	, ,			
	function					
	test					
Conjugated	Blood	4.7 (1.3)	12.6 (6.2)	146.0	-3.1	0.02
Bilirubin	- liver			(57.0)		
(umol/L)	function					
	test					
Albumin	Blood	42.3 (1.7)	40.9 (1.8)	-4.15 (2.9)	2.8	0.028
(g/L)	- liver					
	function					
Caninantal	test	26.2 (4.0)	44 ((E 2)	22 1 (21 0)	2.0	0.092
Conjugated bilirubin	- liver	36.2 (4.0)	44.6 (5.3)	23.1 (21.0)	-2.0	0.092
(%)	function					
(/0)	test					
ALT	Blood	20.8 (5.1)	24.1 (6.5)	17.4 (23.0)	-1.6	0.163
(U/L)	- liver	20.0 (3.1)	24.1 (0.3)	17.4 (25.0)	-1.0	0.103
(0, 1)	function					
	test					
ALP	Blood	67.8 (16.0)	73.9 (21.0)	-0.542	-0.0	0.986
(U/L)	- liver	,	,	(11.0)		
	function					
	test					
Liver	MRI -	0.265	0.0199	-92.3 (2.5)	14.6	0.0
blood	liver	(0.028)	(0.0044)			
clearance						
(L/min)						
R1 at	MRI -	2.33 (0.82)	1.38	-26.1 (3.2)	12.1	0.0
45mins	liver		(0.083)			
(1/sec)	IN ADDI	20 7 (4.5)	2 17 (0 50)	02 ((2.5)	10.6	0.0
Hepatocelli		29.7 (4.5)	2.17 (0.59)	-92.6 (2.5)	10.6	0.0
uptake rate	liver					
(mL/min/1	100cm3)					
RE for Sl	MRI -	66.0 (23.0)	6.54 (1.7)	-87.5 (1.9)	8.8	0.0
at 20min	liver	00.0 (23.0)	0.54 (1.7)	-07.5 (1.5)	0.0	0.0
(%)	livei					
Delta R1	MRI -	1.07 (0.81)	0.136	-77.1 (5.8)	8.7	0.0
at 45mins	liver	(0.01)	(0.03)		***	
(1/sec)			` ′			
AUC	MRI -	205.0	25.8 (4.3)	-81.9 (2.7)	8.6	0.0
for Cl	liver	(100.0)				
(0-35min)						
(mM*sec)						
RE for R11	MRI -	86.9 (40.0)	8.86 (1.5)	-85.6 (1.9)	8.3	0.0
at 20min	liver					
(%)		4 /				
R1 (scan	MRI -	1.73 (0.44)	1.32	-11.7 (4.6)	4.5	0.003
2) (1/sec)	liver		(0.071)			

Biliary excre- tion rate	MRI - liver	2.17 (0.54)	0.791 (0.34)	-48.7 (42.0)	4.1	0.005
(mL/min/		0.450	0.0757	24.4		0.045
Delta R1	MRI -	0.459	0.0757	-31.4	3.1	0.017
(scan 2)	liver	(0.43)	(0.018)	(76.0)		
(1/sec)						
Liver	MRI -	17.7 (6.5)	21.5 (3.3)	264.0	-1.4	0.199
extra-	liver			(420.0)		
cellular						
volume						
fraction						
(mL/100cm	13)					
Extracellula	rMRI -	36.5 (11.0)	43.0 (7.7)	148.0	-0.9	0.406
mean	liver			(240.0)		
transit						
time (sec)						
Extracellula	rMRI -	66.1 (16.0)	70.4 (4.8)	283.0	-0.7	0.531
disper-	liver			(550.0)		
sion				` ′		
(%)						

Table 2.3: Univariate data analysis (liver).

Name	Group	control	drug	Effect size (%)	Т	p-value
Organs extrac- tion fraction	MRI - aorta	18.4 (3.2)	14.1 (3.2)	-25.4 (12.0)	4.0	0.005
(%) RE for R1b at 20min	MRI - aorta	20.6 (9.1)	22.9 (5.9)	45.2 (28.0)	-3.6	0.008
(%) AUC for Cb (0-35min)	MRI - aorta	36.9 (16.0)	35.2 (8.1)	26.8 (16.0)	-3.5	0.011
(mM*sec) Body ex- traction fraction	MRI - aorta	6.73 (2.1)	3.46 (0.77)	-41.1 (16.0)	3.0	0.02
(%) Heart- lung disper- sion	MRI - aorta	47.3 (8.7)	47.4 (8.0)	10.7 (9.8)	-2.0	0.087
(%) RE for Sb at 20min (%)	MRI - aorta	15.3 (8.6)	20.2 (7.4)	136.0 (130.0)	-1.4	0.211
Organs extravas- cular mean	MRI - aorta	5.98 (1.3)	6.72 (1.3)	31.4 (48.0)	-1.0	0.336
transit time (min)						
Organs blood mean transit	MRI - aorta	27.9 (5.5)	30.8 (7.0)	9.7 (20.0)	-0.8	0.464
time (sec) Heart- lung mean	MRI - aorta	14.5 (3.3)	14.5 (2.5)	11.9 (23.0)	-0.7	0.514
transit time (sec) Cardiac output (L/min)	MRI - aorta	7.75 (2.0)	7.7 (1.2)	17.8 (27.0)	-0.6	0.54

Table 2.4: Univariate data analysis (aorta).

3 Supplements




Figure 3.1: Clustering of parameters and subjects.